LOXL2 and pulmonary fibrosis: We have previously identified that PXS-S2A at LOXL2-selective doses inhibits PYD collagen cross-linking and reduces tissue stiffness within the 3D spheroid model, confirming findings within an in vivo rat model of lung fibrosis driven by transient overexpression of active TGF-β1 by adenoviral vector gene transfer.15